HC Wainwright Reiterates Buy Rating for Daré Bioscience (NASDAQ:DARE)

Daré Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 277.36% from the company’s previous close.

Daré Bioscience Trading Down 0.3 %

DARE opened at $3.18 on Tuesday. The business’s 50 day moving average is $3.55 and its 200-day moving average is $3.70. The stock has a market cap of $27.67 million, a PE ratio of -5.38 and a beta of 1.27. Daré Bioscience has a twelve month low of $3.05 and a twelve month high of $7.56.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC boosted its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.